Document is current
Any future updates will be listed below
-
Authors
Gong, Ke
Guo, Gao
Beckley, Nicole A.
Yang, Xiaoyao
Zhang, Yue
Gerber, David E. https://orcid.org/0000-0002-7812-6741
Minna, John D. https://orcid.org/0000-0002-7776-0767
Burma, Sandeep https://orcid.org/0000-0001-7057-9845
Zhao, Dawen https://orcid.org/0000-0001-6428-1698
Akbay, Esra A. https://orcid.org/0000-0002-4149-2529
Habib, Amyn A. https://orcid.org/0000-0003-4164-9028
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K24CA201543-01, P50CA70907)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Prevention and Research Institute of Texas (RP110708)
Foundation for the National Institutes of Health (RO1CA197796, 1R01CA244212-01A1)
U.S. Department of Veterans Affairs (2I01BX002559-07)
- License Information
-
More Information
Article History
Received: 23 February 2021
Accepted: 9 November 2021
First Online: 1 December 2021
Competing interests
: The Department of Veteran’s Affairs has filed a patent for the combined use of EGFR inhibitors plus prednisone in lung cancer with Amyn Habib as the inventor. The other authors declare no competing interests.
